Literature DB >> 12655603

Identification of differentially expressed proteins in human glioblastoma cell lines and tumors.

Rulin Zhang1, Tammy-Lynn Tremblay, Angela McDermid, Pierre Thibault, Danica Stanimirovic.   

Abstract

An in-frame deletion of 801 bp in exons 2-7 (type III mutation) of the epidermal growth factor receptor (EGFR) is detected at high incidence in primary glioblastoma tumors. A proteomic approach was used to generate differential protein expression maps of fetal human astrocytes (FHA), human glioblastoma cell lines U87MG and U87MG expressing type III EGFR deletion (U87MGdeltaEGFR) that confers high malignancy to tumor cells. Two-dimensional gel electrophoresis followed by in-gel digestion of separated spots and protein identification by LC-MS-MS and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) identified 23 proteins expressed at higher levels or exclusively in FHA and 29 proteins expressed at higher levels or exclusively in U87MG cells. Three proteins, ubiquitin, cystatin B, and tissue transglutaminase (TTG), were upregulated in U87MGdeltaEGFR relative to U87MG. Four proteins highly expressed by U87MG cells, Hsp27, major vault protein, TTG, and cystatin B, were analyzed by Western blot, ELISA, or RT-PCR in cell extracts and in tissue samples of glioblastoma multiforme (GBM; grade IV), low-grade astrocytomas (grades I and II), and nonmalignant brain lesions. All four proteins were highly expressed in GBM tissues compared to nonmalignant brain. These proteins may be used as diagnostic or functional (e.g., multiple drug resistance, invasiveness) markers for glioblastoma tumors. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655603     DOI: 10.1002/glia.10222

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  37 in total

1.  Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion.

Authors:  Robert C Rostomily; Donald E Born; Richard P Beyer; Jinghua Jin; Ellsworth C Alvord; Andrei M Mikheev; Russell T Matthews; Catherine Pan; Leila Khorasani; Josh A Sonnen; Thomas J Montine; Min Shi; Jing Zhang
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

2.  Two isoforms of tissue transglutaminase mediate opposing cellular fates.

Authors:  Marc A Antonyak; Jaclyn M Jansen; Allison M Miller; Thi K Ly; Makoto Endo; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

3.  Effects of tissue transglutaminase on beta -amyloid1-42-induced apoptosis.

Authors:  Joseph J Wakshlag; Marc A Antonyak; Jason E Boehm; Karen Boehm; Richard A Cerione
Journal:  Protein J       Date:  2006-01       Impact factor: 2.371

4.  Rosmarinic acid and siRNA combined therapy represses Hsp27 (HSPB1) expression and induces apoptosis in human glioma cells.

Authors:  Aslıhan Şengelen; Evren Önay-Uçar
Journal:  Cell Stress Chaperones       Date:  2018-04-07       Impact factor: 3.667

5.  A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival.

Authors:  Lindsey K Boroughs; Marc A Antonyak; Richard A Cerione
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

Review 6.  Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Authors:  Y Rajesh; Ipsita Pal; Payel Banik; Sandipan Chakraborty; Sachin A Borkar; Goutam Dey; Ahona Mukherjee; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2017-03-20       Impact factor: 6.150

7.  Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK.

Authors:  Marius Grzelinski; Florian Steinberg; Tobias Martens; Frank Czubayko; Katrin Lamszus; Achim Aigner
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

8.  Tissue transglutaminase-1 promotes stemness and chemoresistance in gastric cancer cells by regulating Wnt/β-catenin signaling.

Authors:  Haitao Huang; Zhiqi Chen; Xiuqin Ni
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

9.  EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation.

Authors:  Bo Li; Marc A Antonyak; Joseph E Druso; Le Cheng; Alexander Yu Nikitin; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.

Authors:  Jin-Chul Heo; Tae-Hoon Jung; Sungjin Lee; Hyun Young Kim; Gildon Choi; Myungeun Jung; Daeyoung Jung; Heung Kyoung Lee; Jung-Ok Lee; Ji-Hwan Park; Daehee Hwang; Ho Jun Seol; Heeyeong Cho
Journal:  Clin Exp Metastasis       Date:  2016-03-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.